ArticleJBRA assisted reproduction2025
Association between anti-Mullerian hormone and antithyroid antibodies detectability and positivity in women assisted at a fertility clinic.
Article in JBRA assisted reproduction, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the association between antithyroid antibodies detectability and positivity and ovarian reserve. Additionally, we aimed to evaluate the correlation between TSH levels and parameters of ovarian reserve [anti-Mullerian (AMH) levels and antral follicle count (AFC)].
methodsSubjects were women seeking assisted reproductive therapy and oocyte cryopreservation. AMH, AFC and antithyroid antibodies were determined. In a subgroup of patients, antithyroid antibodies were stratified into categories for the association analyses. The reference values were as follows: antithyroid peroxidase antibody (TPOAb): undetectable (<9 IU/mL), low detectable (9-21 IU/mL), high detectable (22-34 IU/mL), and positive (> 34 IU/mL); antithyroglobulin antibody (TgAb): undetectable (< 10 IU/mL), low detectable (10-60 IU/mL), high detectable (61-115 IU/ mL), and positive (>115 IU/mL). AMH levels < 1.1 ng/mL and/or AFC < 7 follicles were considered to indicate low ovarian reserve.
resultsA total of 453 patients were enrolled. 24.4% had at least one positive antithyroid antibody. Low detectable values for TPOAb and TgAb were found in 42.3% and 66.9%, respectively. TPOAb and TgAb levels were not statistically different between women with AMH < or ≥ 1.1 ng/mL; there was also no statistically significant difference between antithyroid antibodies levels and AFC < or ≥ 7 follicles. AMH levels did not show significant association with detectability nor positivity of the antithyroid antibodies. No statistically significant correlation was observed between AMH and TSH nor AFC and TSH.
conclusionsAlthough the detectability of TPOAb has been associated with different outcomes, TPOAb and/or TgAb were not associated with ovarian reserve in our study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.